296 related articles for article (PubMed ID: 36248712)
61. [Long-term efficacy of low-dose rituximab treatment in patients with primary membranous nephropathy].
Qi Y; Jia JY; Gu QH; Zheng ZF; Li LN; Li D; Jia ZH; Xue Y; Yan TK
Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(40):3201-3206. PubMed ID: 36319174
[No Abstract] [Full Text] [Related]
62. Quantitative detection of anti-PLA2R antibodies targeting different epitopes and its clinical application in primary membranous nephropathy.
Qin Y; Wu Q; Sheng H; Li T; Liu X; Yang X; Lin B; Zhou X; Jin J; Wang L; Huang B; He Q; Hu Z
Clin Chem Lab Med; 2023 Jan; 61(2):251-259. PubMed ID: 36351699
[TBL] [Abstract][Full Text] [Related]
63. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
[TBL] [Abstract][Full Text] [Related]
64. M-Type Phospholipase A2 Receptor Autoantibody Measured by ELISA has Diagnostic Value in Patients with Idiopathic Membranous Nephropathy.
Li J; Mulatibieke A; Liu S; Adelibieke Y; Dai C; Chahan S; Chen H
Clin Lab; 2023 Jun; 69(6):. PubMed ID: 37307127
[TBL] [Abstract][Full Text] [Related]
65. [Diagnostic value of renal phospholipase A2 receptor and serum anti-phospholipase A2 receptor antibody in membranous nephropathy].
Wu X; Wen S; Zhu X; Yuan S; Xu X; Yang D; Sun L; Liu H; Liu F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Apr; 42(4):395-399. PubMed ID: 28490696
[TBL] [Abstract][Full Text] [Related]
66. Diagnostic efficacy of serum anti-phospholipase A2 receptor antibodies for idiopathic membranous nephropathy in patients with diabetic kidney disease.
Wang Q; Dong ZY; Zhang WG; Liu XM; Qu YL; Duan SW; Huang MJ; Zhou JH; Chen P; Zhu HY; Zhang L; Sun XF; Cai GY; Chen XM
Clin Chim Acta; 2020 Mar; 502():222-226. PubMed ID: 31730818
[TBL] [Abstract][Full Text] [Related]
67. Anti-Phospholipase A2 Receptor Antibody as Prognostic Indicator in Idiopathic Membranous Nephropathy.
Kim YG; Choi YW; Kim SY; Moon JY; Ihm CG; Lee TW; Jeong KH; Yang SH; Kim YS; Oh YJ; Lee SH
Am J Nephrol; 2015; 42(3):250-7. PubMed ID: 26484659
[TBL] [Abstract][Full Text] [Related]
68. [Membranous nephropathy: New insights in therapeutic approach].
Dahan K
Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
[TBL] [Abstract][Full Text] [Related]
69. Circulating antibodies against M-type phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in Chinese patients with membranous nephropathy.
Tian C; Li L; Liu T; Qu X; Qiu Y
Int Urol Nephrol; 2019 Aug; 51(8):1371-1377. PubMed ID: 31227982
[TBL] [Abstract][Full Text] [Related]
70. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy.
Hoxha E; Thiele I; Zahner G; Panzer U; Harendza S; Stahl RA
J Am Soc Nephrol; 2014 Jun; 25(6):1357-66. PubMed ID: 24610926
[TBL] [Abstract][Full Text] [Related]
71. The application of podocyte antigen PLA2R and anti-PLA2R antibody in the diagnosis and treatment of membranous nephropathy.
Chen Y; Xu Y; Chen S; Yu Y; Zhu X; Chen J
Ren Fail; 2023; 45(2):2264939. PubMed ID: 37814415
[TBL] [Abstract][Full Text] [Related]
72. A cohort study of membranous nephropathy, primary or secondary.
Arghiani M; Zamani BH; Nazemian F; Samadi S; Afsharian MS; Habibzadeh M; Eslami S; Sabbagh MG
BMC Nephrol; 2021 Apr; 22(1):138. PubMed ID: 33874909
[TBL] [Abstract][Full Text] [Related]
73. Relationship between the status of phospholipase A2 receptor and prognosis of idiopathic membranous nephropathy.
Li YQ; Liu ZZ; Lin KX; Liu RH; Ni L; Liu GX; Lan HY; Shi YJ
Nephrology (Carlton); 2020 Feb; 25(2):144-149. PubMed ID: 31226230
[TBL] [Abstract][Full Text] [Related]
74. Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience.
Chen P; Mao M; Wang C; Zhang X; Zhao X; Gao Y; Luo Y; Zhou Y
Front Endocrinol (Lausanne); 2023; 14():1044782. PubMed ID: 36875477
[TBL] [Abstract][Full Text] [Related]
75. Diagnostic value of phospholipase A2 receptor in idiopathic membranous nephropathy: a systematic review and meta-analysis.
Hu SL; Wang D; Gou WJ; Lei QF; Ma TA; Cheng JZ
J Nephrol; 2014 Apr; 27(2):111-6. PubMed ID: 24500886
[TBL] [Abstract][Full Text] [Related]
76. Serum phospholipase A2 receptor antibodies and immunoglobulin G subtypes in adult idiopathic membranous nephropathy: Clinical value assessment.
Cheng G; Liu J; Gilbert A; Cao Y; An C; Lv Z; Wang C; Nie R; Zhang J; Liu Y; Xia M; Li S; Cai H; Li Y; Li Y; Qin X
Clin Chim Acta; 2019 Mar; 490():135-141. PubMed ID: 30605630
[TBL] [Abstract][Full Text] [Related]
77. [A novel approach to rapid induction of remission in primary membranous nephropathy].
Dobronravov VA; Bystrova OB; Kochoyan ZS; Fomicheva EN
Ter Arkh; 2021 Jun; 93(6):706-712. PubMed ID: 36286838
[TBL] [Abstract][Full Text] [Related]
78. Recurrent Membranous Nephropathy After Kidney Transplantation Associated With Phospholipase A2 Receptor and Successfully Treated With Rituximab: A Case Report.
Ishiwatari A; Wakai S; Shirakawa H; Honda K
Transplant Proc; 2018 Oct; 50(8):2565-2568. PubMed ID: 30316399
[TBL] [Abstract][Full Text] [Related]
79. Treatment of rituximab in patients with idiopathic membranous nephropathy: a case series and literature review.
Jeon SJ; Kim JH; Noh HW; Lee GY; Lim JH; Jung HY; Cho JH; Choi JY; Kim CD; Kim YL; Park SH
Korean J Intern Med; 2022 Jul; 37(4):830-840. PubMed ID: 35421909
[TBL] [Abstract][Full Text] [Related]
80. Renal Phospholipase A2 Receptor and the Clinical Features of Idiopathic Membranous Nephropathy.
Xu NX; Xie QH; Sun ZX; Wang J; Li Y; Wang L; Liu SJ; Xue J; Hao CM
Chin Med J (Engl); 2017 Apr; 130(8):892-898. PubMed ID: 28397717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
